UBS AM
RCUS icon

UBS AM’s Arcus Biosciences RCUS Stock Holding History

UBS AM’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76M Sell
154,398
-3,894
-2% -$96.2K ﹤0.01% 1634
2026
Q1 		$3.42M Buy
158,292
+14,199
+10% +$307K ﹤0.01% 1768
2025
Q4 		$3.43M Buy
144,093
+56,322
+64% +$1.15M ﹤0.01% 1646
2025
Q3 		$1.19M Sell
87,771
-85,827
-49% -$892K ﹤0.01% 1950
2025
Q2 		$1.41M Buy
173,598
+76,175
+78% +$651K ﹤0.01% 2291
2025
Q1 		$765K Buy
97,423
+35,409
+57% +$411K ﹤0.01% 2407
2024
Q4 		$923K Sell
62,014
-7,872
-11% -$129K ﹤0.01% 2399
2024
Q3 		$1.07M Sell
69,886
-26,966
-28% -$425K ﹤0.01% 2363
2024
Q2 		$1.48M Sell
96,852
-281,211
-74% -$4.54M ﹤0.01% 2158
2024
Q1 		$7.14M Sell
378,063
-20,603
-5% -$356K ﹤0.01% 1118
2023
Q4 		$7.61M Sell
398,666
-7,381
-2% -$118K ﹤0.01% 1091
2023
Q3 		$7.29M Sell
406,047
-5,253
-1% -$106K ﹤0.01% 1063
2023
Q2 		$7.5M Hold
411,300
– – ﹤0.01% 1071
2023
Q1 		$7.5M Buy
411,300
+9,531
+2% +$182K ﹤0.01% 1071
2022
Q4 		$8.31M Sell
401,769
-44,965
-10% -$1.24M ﹤0.01% 1008
2022
Q3 		$11.7M Sell
446,734
-3,821
-0.8% -$101K 0.01% 906
2022
Q2 		$11.4M Buy
450,555
+136,717
+44% +$3.35M 0.01% 910
2022
Q1 		$9.9M Buy
313,838
+72,627
+30% +$2.43M ﹤0.01% 1070
2021
Q4 		$9.76M Buy
241,211
+199,634
+480% +$7.74M ﹤0.01% 1134
2021
Q3 		$1.45M Buy
41,577
+4,557
+12% +$142K ﹤0.01% 1974
2021
Q2 		$1.02M Buy
37,020
+3,634
+11% +$104K ﹤0.01% 2209
2021
Q1 		$937K Sell
33,386
-4,329
-11% -$151K ﹤0.01% 2124
2020
Q4 		$979K Buy
37,715
+14,915
+65% +$361K ﹤0.01% 2006
2020
Q3 		$391K Sell
22,800
-8,015
-26% -$179K ﹤0.01% 2234
2020
Q2 		$762K Buy
+30,815
New +$832K ﹤0.01% 1920
2018
Q2 		– Sell
-41,652
Closed -$643K – 2801
2018
Q1 		$643K Buy
+41,652
New +$694K ﹤0.01% 1929

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

UBS AM's RCUS Position: Q2 2026 in Review

UBS AM reduced its Arcus Biosciences (RCUS) stake by 2.5% in Q2 2026, selling an estimated $96.2K and leaving 154,398 shares worth $4.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1634.

UBS AM first reported a position in RCUS in Q1 2018 and has held it in 26 quarters since. The position peaked at $11.7M in Q3 2022. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • UBS AM held 154,398 shares of Arcus Biosciences worth $4.76M as of Q2 2026.
  • UBS AM sold 3,894 Arcus Biosciences shares in Q2 2026, an estimated $96.2K.
  • Arcus Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1634 holding.
  • UBS AM first reported a position in Arcus Biosciences in Q1 2018 and has held it in 26 quarters since.
  • UBS AM's Arcus Biosciences position peaked at $11.7M in Q3 2022.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.